Impact of Personalized Dosing of Faricimab on Treatment Outcomes in nAMD

Video

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
Related Content
Seville, Spain, and the Giralda of Seville, in June 2018. Image credit: ©Julián Maldonado – stock.adobe.com

The Congress on Controversies in Ophthalmology (COPHy) highlights debates in surgical, medical retina

Hattie Hayes
April 4th 2025
Article
International study illuminates economic burden of late-stage age-related macular degeneration

International study illuminates economic burden of late-stage age-related macular degeneration

Lynda Charters
April 1st 2025
Article
Study: No significant long-term benefits found in cocoa extract for AMD

Study: No significant long-term benefits found in cocoa extract for AMD

Lynda Charters
March 31st 2025
Article
Opthea discontinues COAST and ShORe trials in wet AMD

Opthea discontinues COAST and ShORe trials in wet AMD

Martin David Harp
March 31st 2025
Article
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Martin David Harp
March 25th 2025
Article
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

Lynda Charters
March 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.